Niagen Bioscience, Inc. — fact timeline

Niagen Bioscience, Inc. reported first quarter of 2026 results: revenue $31.5 million, net income $6.3 million, EPS $0.08 and $0.07, respectively. Guidance reaffirmed.

“Niagen Bioscience, Inc. Reports First Quarter 2026 Financial Results Net sales increased to $31.5 million Gross margin improved to 63.5% Net income of $6.3 million, up $1.3 million from the prior year and adjusted EBITDA of $3.8 million LOS ANGELES, CA - May 6, 2026 - Niagen Bioscience, Inc. (NASDAQ:NAGE) today announced financial results for the first quarter of 2026.”

Niagen Bioscience, Inc. reported financial results for the fourth quarter and the year ended December 31, 2025.

“On March 4, 2026, Niagen Bioscience, Inc. (the “Company”) issued a press release announcing its financial results for the fourth quarter and the year ended December 31, 2025.”

Niagen Bioscience, Inc. entered into Agreement with Queen’s University Belfast valued at approximately $1,000,000 (effective 2025-12-16).

“On December 18, 2025, ChromaDex, Inc. (the “Company”), a wholly owned subsidiary of Niagen Bioscience, Inc. (the “Registrant”), executed an assignment agreement (the “Agreement”) with Queen’s University Belfast (“QUB”), with an effective date of December 16, 2025.”

Niagen Bioscience, Inc.: Company amended Certificate of Incorporation to change name to Niagen Bioscience, Inc (effective 2025-03-19).

“On March 17, 2025, Niagen Bioscience, Inc. (formerly ChromaDex Corporation) (the “Company”) amended its Amended and Restated Certificate of Incorporation (the “Certificate of Incorporation”) to change the Company’s name to “Niagen Bioscience, Inc.,” effective as of 12:01 a.m. Eastern Time on March 19, 2025.”

Niagen Bioscience, Inc. engaged Crowe LLP as its auditor.

“the Audit Committee approved the engagement of Crowe LLP (“Crowe”) as the Company’s independent registered public accounting firm for the fiscal year ending December 31, 2024, effective December 13, 2024.”

Marcum LLP resigned as auditor of Niagen Bioscience, Inc..

“On October 8, 2024, Marcum LLP (“Marcum”) notified ChromaDex Corporation (the “Company”) that it was resigning, effective October 31, 2024, as the independent registered public accounting firm for the Company due to independence concerns relating to Marcum’s impending merger with CBIZ Inc.”

James Lee changed role as Controller at Niagen Bioscience, Inc..

“Mr. Pamir will replace James Lee, who is currently serving as the Company’s Interim Chief Financial Officer and Interim Principal Accounting Officer.”

Ozan Pamir was appointed as Chief Financial Officer and Principal Accounting Officer at Niagen Bioscience, Inc..

“On September 19, 2024, the Board of Directors (the “Board”) of ChromaDex Corporation (the “Company” or “ChromaDex”) appointed Ozan Pamir as the Company’s Chief Financial Officer and Principal Accounting Officer, effective as of October 21, 2024”

James Lee was appointed as Interim Chief Financial Officer and Interim Principal Accounting Officer at Niagen Bioscience, Inc..

“On July 16, 2024, the Board of Directors (the “Board”) of ChromaDex Corporation (the “Company” or “ChromaDex”) appointed James Lee, the Company’s current Controller, as the Company’s Interim Chief Financial Officer and Interim Principal Accounting Officer, effective as of July 13, 2024.”

Brianna Gerber resigned as Chief Financial Officer and Principal Accounting Officer at Niagen Bioscience, Inc..

“As previously disclosed, Brianna Gerber resigned from her roles as the Company’s Chief Financial Officer and Principal Accounting Officer effective July 12, 2024.”

Brianna Gerber departed as Chief Financial Officer and Chief Accounting Officer at Niagen Bioscience, Inc..

“On June 19, 2024, Brianna Gerber, the Chief Financial Officer and Chief Accounting Officer of ChromaDex Corporation (the “Company”), informed the Company that she will be resigning from her roles with the Company, effective July 12, 2024 (the “Separation Date”).”

Niagen Bioscience, Inc. reported first quarter of 2024 results: revenue $22.2 million, net income $0.5 million, EPS $(0.01) per share. Guidance reaffirmed.

“ChromaDex Corporation Reports First Quarter 2024 Financial Results Total net sales of $22.2 million, gross margin of 60.7%, a net loss of $0.5 million and a positive Adjusted EBITDA of $0.7 million for the three months ended March 31, 2024. Reiterated full year outlook including net sales growth of at least 16%.”

Niagen Bioscience, Inc. reported Fiscal Year 2023 results: revenue $83.6 million, net income net loss of only $4.9 million, EPS $0.07 loss per share.

“Full year net sales of $83.6 million, up 16% from the prior year, gross margin of 60.8%, net loss of only $4.9 million, positive Adjusted EBITDA of $1.9 million and positive operating cash flows.”

Niagen Bioscience, Inc. reported Fourth Quarter 2023 results: revenue $21.2 million, net income net income of $0.1 million, EPS $0.00 earnings per share.

“Fourth quarter net sales of $21.2 million, gross margin of 61.0%, and net income of $0.1 million.”

Niagen Bioscience, Inc. amended revolving credit of up to $10.0 million with Western Alliance Bank at 8.25% per year maturing November 12, 2025.

“the “Credit Agreement”) dated November 1, 2019 among the Borrowers and Western Alliance Bank (the “Lender”). The Credit Agreement provides for a revolving credit line of up to $10.0 million. The Amendment extended the maturity date of the revolving credit line under the Credit Agreement to November 12, 2025 and also increased the interest rate to be calculated at a”

Niagen Bioscience, Inc. amended Amendment to Business Financing Agreement with Western Alliance Bank valued at Revolving credit line of up to $10.0 million; maturity extended to November 12, 2025; interest rate (effective 2023-12-08).

“On December 8, 2023, ChromaDex Corporation (the “Company”), and the Company’s wholly owned subsidiaries, ChromaDex, Inc., a California corporation, and ChromaDex Analytics, Inc., a Nevada corporation (together with the Company, the “Borrowers”) entered into an amendment (the “Amendment”) to the business financing agreement (as amended, the “Credit Agreement”) dated November 1, 2019 among the Borrowers and Western Alliance Bank (the “Lender”).”

Niagen Bioscience, Inc. reported the third quarter of 2023 results: revenue $19.5 million, net income $1.0 million, EPS $(0.01) per share.

“ChromaDex Corporation Reports Third Quarter 2023 Financial Results Total net sales of $19.5 million, a gross margin of 61.4% and a net loss of $1.0 million while achieving a positive Adjusted EBITDA of $0.5 million and positive operating cash flows for the three months ended September 30, 2023.”

Niagen Bioscience, Inc. reported the second quarter of 2023 results: revenue $20.3 million, net income $2.2 million, EPS $(0.03) per share. Guidance raised.

“by specific reference in such filing. --- EX-99.1 (EX-99.1) --- ChromaDex Corporation Reports Second Quarter 2023 Financial Results Strong quarter with total net sales of $20.3 million, a gross margin of 60.8% and a net loss of $2.2 million while achieving a positive Adjusted EBITDA of $0.2 million and positive operating cash flows for the three months ended”

Niagen Bioscience, Inc. shareholders rejected Approval of amendment to the Company’s certificate of incorporation to authorize the issuance of up to 5 million shares of preferred stock.

“Proposal 5 — Approval of amendment to the Company’s certificate of incorporation to authorize the issuance of up to 5 million shares of preferred stock. For Against Abstain Broker Non-Votes 36,184,125 8,688,172 181,120 11,176,909 Based on the votes set forth above, the proposed amendment to the Company’s certificate of incorporation was not approved by the Company’s stockholders.”

Niagen Bioscience, Inc. shareholders approved Approval of amendment to the Company’s 2017 Equity Incentive Plan to increase the number of shares available for issuance by 3.65 million shares of common stock.

“Proposal 4 — Approval of amendment to the Company’s 2017 Equity Incentive Plan to increase the number of shares available for issuance by 3.65 million shares of common stock. For Against Abstain Broker Non-Votes 39,844,772 5,156,391 52,254 11,176,909”

Niagen Bioscience, Inc. shareholders approved Approval, on an advisory basis, of the compensation paid to the Company’s named executive officers.

“Proposal 3 — Approval, on an advisory basis, of the compensation paid to the Company’s named executive officers. For Against Abstain Broker Non-Votes 43,580,102 1,443,544 29,771 11,176,909”

Niagen Bioscience, Inc. shareholders approved Ratification of the appointment of Marcum LLP as the Company's independent registered public accounting firm for the fiscal year ending December 31, 2023 at the 2023-12-31 meeting.

“Proposal 2 — Ratification of the appointment of Marcum LLP as the Company's independent registered public accounting firm for the fiscal year ending December 31, 2023. For Against Abstain Broker Non-Votes 53,073,220 2,985,840 171,266 * * No broker non-votes arose in connection with Proposal 2.”

Niagen Bioscience, Inc. shareholders approved Election of directors.

“Proposal 1 — Election of directors. The following directors were elected to serve until the Company’s 2024 Annual Meeting of Stockholders and until his or her successor is elected, or, if sooner, until such director’s death, resignation or removal. Director Elected For Withheld Broker Non-Votes Frank L. Jaksch, Jr. 43,991,870 1,061,547 11,176,909 Robert Fried 43,766,801 1,286,616 11,176,909 Steven Rubin 36,576,757 8,476,660 11,176,909 Wendy Yu 44,381,475 671,942 11,176,909 Gary Ng 44,320,738 732,679 11,176,909 Kristin Patrick 44,152,241 901,176 11,176,909 Ann Cohen 44,137,364 916,053 11,176,909 Hamed Shahbazi 43,164,410 1,889,007 11,176,909”

Niagen Bioscience, Inc. reported the three months ended March 31, 2023 results: revenue $22.6 million, net income $1.9 million, EPS $(0.03) per share.

“ChromaDex Corporation Reports First Quarter 2023 Financial Results Record net sales of $22.6 million, with a strong gross margin of 59.9%, lower operating expenses, and a net loss and Adjusted EBITDA loss of only $1.9 million and $0.1 million, respectively, for the three months ended March 31, 2023.”

Niagen Bioscience, Inc.: Amended and restated bylaws to accommodate universal proxy rules, revise advance notice provisions, address DGCL changes, and make administrative changes (effective 2023-03-16).

“On March 16, 2023, the Board of Directors (the “Board”) of ChromaDex Corporation (the “Company”) amended and restated the Amended and Restated Bylaws of the Company (as so amended and restated, the “Amended and Restated Bylaws”) in order to, among other things (i) revise and enhance certain provisions to accommodate the universal proxy rules adopted by the Securities and Exchange Commission (Rule 14a-19), (ii) revise the information and other requirements of the Company’s advance notice provisions for stockholder proposals and nominations, (iii) address changes in the Delaware General Corporations Law relating to the provision of a list of stockholders in connection with stockholder meetings and (iv) make certain administrative and clarifying changes.”

Niagen Bioscience, Inc. reported financial results for fourth quarter and the year ended December 31, 2022.

“On March 8, 2023, ChromaDex Corporation (the “Company”) issued a press release announcing its financial results for the fourth quarter and the year ended December 31, 2022.”

Brianna Gerber was appointed as Chief Financial Officer at Niagen Bioscience, Inc..

“appointed Brianna Gerber as Chief Financial Officer of the Company, effective as of January 1, 2023.”

Niagen Bioscience, Inc. reported the quarter ended September 30, 2022 results: revenue $17.1 million, net income $1.0 million or $(0.01) per share, EPS $(0.01) per share.

“ChromaDex Corporation Reports Third Quarter 2022 Financial Results Total net sales of $17.1 million”

Hamed Shahbazi was appointed as Director at Niagen Bioscience, Inc..

“On August 8, 2022, the Board appointed Hamed Shahbazi as a member of the Board effective as of August 9, 2022, to serve until the Company’s 2023 annual meeting of stockholders and until his successor is duly elected and qualified.”

Brianna Gerber was appointed as SVP, Finance / Interim Chief Financial Officer at Niagen Bioscience, Inc..

“On August 10, 2022, the Board of Directors of ChromaDex (the “Board”) appointed Brianna Gerber as SVP, Finance / Interim Chief Financial Officer, effective as of August 11, 2022, to replace the vacancy created by Mr. Farr’s termination as disclosed in item (a) above.”

Kevin Farr departed as Chief Financial Officer at Niagen Bioscience, Inc..

“On August 10, 2022, Kevin Farr was terminated without cause as Chief Financial Officer of the Company, and as an officer, employee, and director of the Company and any subsidiaries of the Company in which he serves in any of those capacities, effective as of August 12, 2022.”

Frank L. Jaksch, Jr. resigned as Executive Director at Niagen Bioscience, Inc..

“On June 3, 2022, Frank L. Jaksch, Jr. notified ChromaDex Corporation (the “Company”) of his intention to resign as executive director and employee of the Company”

Ann Cohen was appointed as Director at Niagen Bioscience, Inc..

“On April 15, 2022, the Board appointed each of Kristin Patrick and Ann Cohen as a member of the Board effective as of such date, to serve until the Company’s Annual Meeting.”

Kristin Patrick was appointed as Director at Niagen Bioscience, Inc..

“On April 15, 2022, the Board appointed each of Kristin Patrick and Ann Cohen as a member of the Board effective as of such date, to serve until the Company’s Annual Meeting.”

Caroline Levy resigned as Director at Niagen Bioscience, Inc..

“On April 11, 2022, Caroline Levy notified the Company of her intention to resign from the Board and as a member of the Audit Committee and Nominating and Corporate Governance Committee of the Board.”

Kurt Gustafson departed as Director at Niagen Bioscience, Inc..

“On April 5, 2022, Kurt Gustafson notified ChromaDex Corporation (the “Company”) of his intention not to stand for re-election as director of Board of Directors of the Company (the “Board”) and as a member of the Audit Committee and Compensation Committee of the Board.”

Jeffery Baxter resigned as Director at Niagen Bioscience, Inc..

“On April 4, 2022, Jeffery Baxter notified ChromaDex Corporation (the “Company”) of his intention to resign from the board of directors of the Company (the “Board”) and as a member of the Audit Committee and Nominating and Corporate Governance Committee of the Board.”

Gary Ng was appointed as member of the Board at Niagen Bioscience, Inc..

“On December 13, 2021, the Board of Directors (the “Board”) of ChromaDex Corporation (the “Company”) increased the size of the Board from eight to nine members and appointed Gary Ng as a member of the Board effective on such date, to serve until the Company’s 2022 annual meeting of stockholders.”

Caroline S. Levy was appointed as Director at Niagen Bioscience, Inc..

“On December 1, 2021, the Board of Directors (the “Board”) of ChromaDex Corporation (the “Company”) appointed Caroline S. Levy as a member of the Board effective on such date, to serve until the Company’s 2022 annual meeting of stockholders.”

Tony Lau resigned as director at Niagen Bioscience, Inc..

“On October 19, 2021, Tony Lau notified ChromaDex Corporation (the “Company”) of his intention to resign from the board of directors of the Company (the “Board”) and as a member of the Compensation Committee of the Board.”